Lexicon Pharmaceuticals, Inc. (LXRX) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は The Woodlands, TX, アメリカ. 現CEOは Michael S. Exton.
LXRX を有する IPO日 2000-04-07, 103 名の正社員, に上場 NASDAQ Global Select, 時価総額 $741.44M.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
